Does Obesity Interfere With Anastrozole Treatment? Positive Association Between Body Mass Index and Anastrozole Plasma Levels
- 1 August 2014
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 14 (4) , 291-296
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancerBritish Journal of Cancer, 2013
- Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass indexBritish Journal of Cancer, 2012
- Aromatase Inhibition in Obese Women: How Much Is Enough?Journal of Clinical Oncology, 2012
- Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 TrialJournal of Clinical Oncology, 2011
- Effect of Obesity on Prognosis After Early-Stage Breast CancerJournal of Clinical Oncology, 2011
- Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical studyAnalytical and Bioanalytical Chemistry, 2010
- Commentary on: “Effect of obesity on survival in women with breast cancer: systematic review and meta-analysis” (Melinda Protani, Michael Coory, Jennifer H. Martin)Breast Cancer Research and Treatment, 2010
- Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC TrialJournal of Clinical Oncology, 2010
- Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceAnnals of Oncology, 2004
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976